Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438216 | 0.93 | MAPT (0.37) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL2438220 | 0.91 | MAPT (0.36) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL2906720 | 0.87 | MAPT (0.39) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL1058524 | 0.86 | MAPT (0.38) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL2435295 | 0.84 | MAPT (0.37) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL1058528 | 0.83 | MAPT (0.39) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL2438222 | 0.83 | MAPT (0.36) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL2435292 | 0.82 | MAPT (0.38) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL1058529 | 0.81 | ALDH1A1 (0.39) | RECQLTSHRHDAC6MAPTNPC1 | |
| SCHEMBL6010495 | 0.80 | HTT (0.40) | RECQLKMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1697344-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058841-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | RECQL 2900/4885TSHR 4854/4885HDAC6 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.